PLATFORM TECHNOLOGY AND PIPELINE OVERVIEW

Palena Therapeutics is focused on developing a portfolio of immunomodulatory peptides, termed embedded epitope random peptides (EERPs) for the treatment of a broad range of autoimmune diseases. Embedded Epitope Random Peptides are a second-generation improved class of random copolymer therapeutics that were initially commercialized in 1997. EERPs are designed to more specifically interact with MHC class II proteins, thus blocking the first step in the development or perpetuation of many autoimmune diseases. Furthermore, these immunomodulatory peptides are intended to selectively inhibit the autoimmune cascade by affecting the T-B cell axis shown to mediate many autoimmune disorders similar to Copaxone® in the treatment of relapsing remitting multiple sclerosis. By selectively inhibiting the antigen presentation step by preventing binding of the self-antigens to the MHC class II molecule, EERPs can disrupt the immune systems attack on the body while not interfering with the immune system’s ability to respond to infectious diseases. The ability of EERPs to maintain a normal functioning immune system while efficaciously inhibiting the initial step of an autoimmune disorder will offer a significant commercial and marketing advantage over current disease modifying therapies. Palena plans to conduct a Phase 1/2a clinical study in relapsing remitting multiple sclerosis (RRMS) subjects to demonstrate the safety and value of its embedded epitope random peptides. The Company then anticipates expanding its clinical trials to include the orphan indications Pediatric MS and Autoimmune Uveitis.